Skip to main content
. 2014 Dec 15;3:31–36. doi: 10.5414/CNCS108420

Table 1. Summary of the clinical, laboratory, and pathology features of 7 patients (including the current case report) presenting with glomerulopathies associated with pulmonary alveolar proteinosis.

Reference Age/Sex Type of acquired PAP Relevant serological studies Treatment of PAP Serum creatinine (mg/dL) Urinary protein finding Kidney pathology finding Specific treatment Outcome
Ganguli et al. [27] (1972) 21/M Idiopathic – None – 2+ protein Amyloidosis* Prednisone Death
Parto et al. [18] (1994) 10/F Secondary (lysinuric protein intolerance – None – 2.2 g/L Diffuse Glomerulonephritis* None Death
13/F Secondary (lysinuric protein intolerance – None 0.85 – Mesangial Glomerulonephritis* None Death
7/F Secondary (lysinuric protein intolerance – None 3.15 – Membranous nephropathy* None Death
Witzke et al. [28] (2004) 38/F Secondary (immunodeficiency syndrome with absence of monocytes) – Whole-lung lavage Normal 4.2 g/day Membranous nephropathy Prednisone Death
Yamada et al. [29] (2007) 47/F Secondary Absence of anti-GM-CSF antibody; presence of anti-α enolase antibody None 0.56 3.2 g/day Membranous nephropathy None Spontaneous remission of PAP and nephrotic syndrome
Sewaralthahab (present case) (2014) 43/F Idiopathic Absence of anti-PLA2R antibody Whole-lung lavage and sargramostim therapy with clinical remission 0.74 3.1 g/g of creatinine Membranous nephropathy De-escalation of sargramostim therapy Remission of nephrotic syndrome

PAP = pulmonary alveolar proteinosis; M = male; F = female; GM-CSF = granulocyte-macrophage colony stimulating factor; Note: Conversion factor for units: SCr in mg/dL to mmol/L, 388.4. *by autopsy.